Antibodies to activated T cells and their soluble products in systemic lupus erythematosus.

Arthritis & Rheumatology (Impact Factor: 7.76). 07/1982; 25(7):814-9. DOI: 10.1002/art.1780250720
Source: PubMed
0 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Systemic lupus erythematosus (SLE) is a nonspecific autoimmune disorder which may involve any organ. Although its etiology is still unclear, some of its pathogenetic aspects as well as the spectrum of its clinical manifestations and a variety of indicators of disease activity have become increasingly known over the past decades. In conjunction with improved diagnostic modalities, this knowledge has lately made possible (a) earlier recognition, (b) an increase in diagnostic accuracy, and (c) improved therapeutic approaches. At present, SLE may therefore be considered a well controllable disease provided it is recognized early and treated appropriately.
    No preview · Chapter · Jan 1987
  • [Show abstract] [Hide abstract]
    ABSTRACT: The clinical outcome of patients with the various manifestations of collagen vascular disease (CVD) has significantly improved over the past two decades with the increased use of diuretics, cytotoxic agents, dialysis, transplantation, and the judicious use of corticosteroids and other antiinflammatory agents directed at altering or delaying end-organ damage by the underlying immunopathologic process. A more rigorous definition of the various CVD clinical syndromes and a greater sophistication in the serologic, radiologic, and pathologic diagnostic methods have meant that patients with these diseases are now coming to clinical attention earlier in the course of their illness. Consequently, the physician is now encountering a greater number of clinical problems over a longer time span for each individual patient, rather than just the well-known complications of their end-stage disease. Despite the beneficial aspects of the newer therapeutic interventions to improve the clinical outcome of patients with CVD, the incidence of infection as a cause of both morbidity and mortality in these patients has not changed significantly over the past 30 years. A number of factors discussed in this chapter most likely contribute to the persistence of infectious complications in these patients. These include underlying host-defense abnormalities not significantly altered by therapeutic interventions, prolonged therapy with corticosteroids and alkylating agents that further suppress an already abnormal immune response, and an increased frequency of hospitalizations with more aggressive medical and surgical interventions, thereby increasing the risk of nosocomial infectious complications.
    No preview · Chapter · Jan 1994
  • Source

    Preview · Article · Feb 1997 · Transactions of the American Clinical and Climatological Association
Show more